 "Aurobindo gets final USFDA nod for anti-fungal drug")
Aurobindo Pharma Limited today announced it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Voriconazole tablets.
The company expects to launch the product in the current quarter.
The approved generic product is bioequivalent and therapeutically equivalent to the reference listed drug product VFEND Tablets of PF Prism C V, the company said.
Voriconazole tablets are used to fungal infections for patients of 12 years of age and above. The product has an estimated market size of $103 million for the twelve months ending November 2015, the company quoted IMS data.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app